Quick Answer
CITIUS ONCOLOGY, INC. reported Stockholders Equity of $44.87 million for the year ending 2025.
- CITIUS ONCOLOGY, INC. showed a decrease of -2.8% in Stockholders Equity from 2024 to 2025.
- This data is from CITIUS ONCOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on December 23, 2025.
- XBRL data for this metric is available from 2021 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$9.4 thousand | Q2 2021: -$10.1 thousand | Q3 2021: -$10.1 thousand | Q1 2022: -$10.1 thousand | Q2 2022: -$10.1 thousand | Q4 2022: $345.5 thousand | Q1 2023: $197.6 thousand | Q2 2023: -$2.0 thousand | Q4 2023: $22.73 million | Q1 2024: $19.85 million | Q2 2024: $17.03 million | Q3 2024: $46.14 million | Q4 2024: $41.29 million | Q1 2025: $35.64 million | Q2 2025: $32.40 million | Q3 2025: $44.87 million | Q4 2025: $58.41 million.
- Over the full 7 years of available data (2021 to 2025), CITIUS ONCOLOGY, INC.'s Stockholders Equity has grown by 443,749.1%.
- Historical annual values: Fiscal year 2025: $44.87 million | Fiscal year 2024: $46.14 million | Fiscal year 2023: -$1.99 million | Fiscal year 2023: $25.54 million | Fiscal year 2022: $345.5 thousand | Fiscal year 2022: $36.27 million | Fiscal year 2021: -$10.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: